Eliem Therapeutics, Inc. (ELYM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELYM Stock Price Chart Interactive Chart >
ELYM Price/Volume Stats
| Current price | $3.43 | 52-week high | $29.69 |
| Prev. close | $3.15 | 52-week low | $2.52 |
| Day low | $3.18 | Volume | 57,800 |
| Day high | $3.60 | Avg. volume | 143,500 |
| 50-day MA | $5.92 | Dividend yield | N/A |
| 200-day MA | $12.25 | Market Cap | 91.13M |
Eliem Therapeutics, Inc. (ELYM) Company Bio
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Latest ELYM News From Around the Web
Below are the latest news stories about Eliem Therapeutics Inc that investors may wish to consider to help them evaluate ELYM as an investment opportunity.
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceSEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 3:00 PM ET. |
Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced it will host a virtual investor event, featuring two opinion leaders in chronic pain, that will be held on Wednesday, February 16 |
Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term MilestonesETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depression (PMD) Patient dosing underway for ETX-155 Phase 1b proof-of-concept study in epilepsy SEATTLE and CAMBRIDGE, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developi |
Leerink Partners Thinks Eliem Therapeutics’ Stock is Going to RecoverIn a report issued on December 17, Marc Goodman from Leerink Partners reiterated a Buy rating on Eliem Therapeutics (ELYM – Research Report), with a price target of $33.00. The company's shares closed last Wednesday at $10.01, close to its 52-week low of $8.16. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eliem Therapeutics. |
Eliem Therapeutics (NASDAQ:ELYM) Shares Down 3.8%Eliem Therapeutics Inc (NASDAQ:ELYM)s stock price fell 3.8% on Wednesday . The stock traded as low as $11.25 and last traded at $11.33. 14,834 shares traded hands during trading, a decline of 89% from the average session volume of 141,003 shares. The stock had previously closed at $11.78. Several research firms have recently weighed in [] |
ELYM Price Returns
| 1-mo | 13.58% |
| 3-mo | -64.86% |
| 6-mo | -74.89% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -67.21% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...